Overture Life — Series C · $20.6M

Overture Life announced what it described as a $20.6M 'strategic funding round' led by returning investor Overwater Ventures with participation from GV and Khosla Ventures, taking total funding to $57M; databases such as Tracxn file it as the company's Series C while Crunchbase lists it as an undesignated venture round. The capital funds clinical trials of the DaVitri platform ahead of FDA clearance and was announced alongside a U.S. CLIA license for its m|z metabolomic embryo-selection test.